Italia markets close in 3 hours 13 minutes

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,72-0,14 (-2,04%)
Alla chiusura: 04:00PM EDT
6,54 -0,18 (-2,68%)
Dopo ore: 07:34PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente6,86
Aperto6,84
Denaro5,02 x 200
Lettera8,30 x 200
Min-Max giorno6,48 - 7,13
Intervallo di 52 settimane1,86 - 9,01
Volume66.330
Media Volume82.572
Capitalizzazione56,055M
Beta (5 anni mensile)1,02
Rapporto PE (ttm)N/D
EPS (ttm)-236,13
Prossima data utili13 mag 2024 - 17 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A16,00
  • GlobeNewswire

    Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

    Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

    HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof)

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

    HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanyin